Trials / Terminated
TerminatedNCT06245941
A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)
A Phase Ib/II Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Moderate- and High-risk Myelofibrosis
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 tablets combined with TQB3909 tablets in patients with moderate- and high-risk Myelofibrosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQ05105 tablets | TQ05105 is a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) Inhibitor |
| DRUG | TQB3909 tablets | TQB3909 is an inhibitor targeting B-cell lymphoma-2 (BCL-2) protein. |
Timeline
- Start date
- 2024-05-13
- Primary completion
- 2025-12-30
- Completion
- 2025-12-30
- First posted
- 2024-02-07
- Last updated
- 2026-01-05
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06245941. Inclusion in this directory is not an endorsement.